Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Compares Stribild To Prezista In Seeking Exclusivity For Fixed Dose Combinations

This article was originally published in The Pink Sheet Daily

Executive Summary

Gilead requests five-year marketing exclusivity for two of the components in its HIV Quad treatment Stribild; citizen petition says award should not depend on whether a new active moiety is approved first as a single entity product or as part of a fixed-dose combination.

You may also be interested in...



All Over But The Lawsuits? NCE Exclusivity For Fixed-Dose Combos Remains Prospective

FDA rejects requests by firms to make new policy retroactive; Gilead’s Harvoni and Eisai’s Akynzeo fixed combos, approved the day FDA issued its final guidance, granted exclusivity.

FDA Changes Its Policy On Exclusivity For Fixed-Combination Products

In response to citizen petitions from Gilead, Ferring and Bayer, FDA issued a draft guidance saying future fixed-combination products that include a previously approved active moiety will be eligible for five years of new chemical entity marketing exclusivity.

Approval Recommendations Set Path For Pfizer’s Xeljanz, Japan Tobacco’s HIV Therapy In Japan

JT’s HIV compound comes home after being joined with Gilead combination therapy. Also approved is Nobelpharma’s glowing red in vivo diagnostic for malignant glioma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel